Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation

University of Calgary20 enrolled

Overview

This two-year observational, open-label clinical trial will evaluate the efficacy of a once-yearly infusion of zoledronic acid after denosumab discontinuation to maintain tissue mineral density and bone microarchitecture using high-resolution peripheral quantitative computed tomography (HR-pQCT) among post-menopausal women with osteoporosis.

As part of an observational study, twenty female osteoporosis patients looking to transition off denosumab therapy will be recruited from the David Hanley Osteoporosis Centre and affiliated primary care physicians in Calgary. The decision to stop denosumab will be made in accordance with standard clinical care and fully separate from the present study. Approximately 6-8 months after the patients' final denosumab injection, patients will receive a single infusion of zoledronic acid (5 mg/100mL) as part of their routine standard of care. The 6-8 month time frame corresponds with the recommended duration between subsequent denosumab injections. Concurrent with zoledronic acid treatment (within one month before or after infusion), patients will visit to the McCaig Institute for Bone and Joint Health to receive a baseline dual X-ray absorptiometry scan (lumbar spine, lateral vertebral assessment, and hip) and a high-resolution peripheral computed tomography scan (radius and tibia) to quantify areal BMD and volumetric BMD/bone microarchitecture, respectively. They will also complete the MoJo Fracture Risk Questionnaire. Patients will return for repeat scanning and questionnaire administrations to monitor potential changes to bone at 6 and 12 months after baseline. Any fracture events during the 12-month time frame will be logged in consultation with the patients' physician as documented through routine clinical follow-up. Researchers may contact participants to repeat scanning and questionnaire administration at the 24-month time point, if participants agree to this contact within the informed consent.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Osteoporosis Osteoporosis, Postmenopausal Osteopenia Bone Loss

Interventions

Zoledronic acidDRUG

Once-yearly infusion of zoledronic acid following denosumab discontinuation

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * Post-menopausal females with osteoporosis * Anticipating or preparing to transition off active denosumab treatment for osteoporosis with the use of a once-yearly infusion of zoledronic acid * Received at least 2 injections of denosumab treatment * Had a recent test (within 6 months) of serum creatine, calcium and phosphate Exclusion Criteria: * Any person for whom zoledronic acid would be considered contraindicated * Pre-menopausal females * Any person with significant chronic kidney disease (eGFR \< 50 ml/m2 at time of osteoporosis clinical assessment) * Any person with previous adverse reactions or allergy to bisphosphonate therapies * Any person with non-corrected hypocalcaemia * Any person currently taking, and unable to discontinue the use of, prohibited medications including: ZOMETA, other bisphosphonate therapies, calcitonin, aminoglycosides, loop diuretics and agiogenesis inhibitors * Any person with other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the Qualified Medical Investigator affect compliance with study requirements or which would make the participant unsuitable for this study * Any person with simultaneous participation in another interventional clinical study (e.g., Phase 1-3 clinical studies) or treatment with any investigational medicinal product within 30 days prior to screening visit

Locations (1)

University of Calgary, McCaig Institute for Bone and Joint Health

Calgary, Alberta, Canada

Outcomes

Primary Outcomes

Change in volumetric Bone Mineral Density (BMD)/bone microarchitecture from baseline

High-resolution peripheral computed tomography scan (radius and tibia) will be used to quantify volumetric BMD/bone microarchitecture

Time frame: Change from Baseline (within 1-month of infusion) to 6-months and 12-months

Change in areal Bone Mineral Density (BMD) from baseline

Dual X-ray absorptiometry scan (lumbar spine, lateral vertebral assessment, and hip) will be used to quantify areal BMD

Time frame: Change from Baseline (within 1-month of infusion) to 6-months and 12-months

Secondary Outcomes

Fractures

Any clinically diagnosed fractures will be reported by treating physician

Time frame: 1 year

MoJo Fracture Risk Questionnaire

An assessment of fracture risk

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.